PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)

• W. Jurczak,
• C. Dartigeas,
• M. Coscia,
• P. Ganly,
• G. Al-Jazayrly,
• C. Wang,
• K. Bao,
• C. C. Leow,
• S. Shahda,
• P. L. Zinzani

Affiliations

W. Jurczak

1 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

C. Dartigeas

2 Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Tours, France

M. Coscia

3 Molecular Biotechnology and Health Sciences, Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

P. Ganly

4 Christchurch Hospital, Christchurch

G. Al-Jazayrly

5 Hollywood Presbyterian Medical Tower, Los Angeles

C. Wang

6 Elli Lily and Company, Indianapolis

K. Bao

7 Loxo Oncology at Lilly, Stamford, United States of America

C. C. Leow

7 Loxo Oncology at Lilly, Stamford, United States of America

S. Shahda

7 Loxo Oncology at Lilly, Stamford, United States of America

P. L. Zinzani

8 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy